Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Cash & Current Investments (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed Cash & Current Investments for 11 consecutive years, with $3.2 million as the latest value for Q3 2025.

  • Quarterly Cash & Current Investments fell 58.38% to $3.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Sep 2025, down 58.38% year-over-year, with the annual reading at $7.5 million for FY2024, 101.79% up from the prior year.
  • Cash & Current Investments hit $3.2 million in Q3 2025 for Aptevo Therapeutics, down from $8.1 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $62.9 million in Q2 2021 to a low of $1.6 million in Q3 2023.
  • Historically, Cash & Current Investments has averaged $22.8 million across 5 years, with a median of $21.0 million in 2023.
  • Biggest five-year swings in Cash & Current Investments: skyrocketed 564.96% in 2021 and later plummeted 92.89% in 2023.
  • Year by year, Cash & Current Investments stood at $45.0 million in 2021, then plummeted by 49.75% to $22.6 million in 2022, then crashed by 83.51% to $3.7 million in 2023, then skyrocketed by 101.79% to $7.5 million in 2024, then plummeted by 57.16% to $3.2 million in 2025.
  • Business Quant data shows Cash & Current Investments for APVO at $3.2 million in Q3 2025, $8.1 million in Q2 2025, and $2.1 million in Q1 2025.